Skip to main content
Equibles
IMNN logo

IMNN · Imunon, Inc. · Webcasts, Transcripts & Audio

Track IMNN — free

Use IMNN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IMNN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.32 +0.08 (+6.59%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$7.91M
Shares
5.61M
Volume · Oct 5 82.72K Avg daily vol (3M) 150.84K

Imunon, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Imunon, Inc. (IMNN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲0% $125,000 −$6.15M '22 Q3 22-11-14 LATEST ▲0% $125,000 −$13.23M '22 Q4 23-03-30
Earnings call
FY26 · Q2
2026-08-11
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Confident tone MRD translational/biomarker validation Phase III Ovation III enrollment momentum Safety profile of Immunon-001
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
Positive tone FDA pathway and overall survival endpoint Phase 2 Ovation 2 results Phase 3 Ovation 3 enrollment
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
Confident tone OVATION 2 Phase II overall survival data OVATION 3 Phase III trial enrollment Regulatory and trial design validation
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript
Confident tone IMNN-001 Clinical Data & Mechanism OVATION 3 Trial Enrollment & Progress Regulatory Pathway & Trial Design
Diluted EPS
$-1.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript
Confident tone IMNN-001 OVATION 3 Phase III Trial OVATION 2 Survival Data and ASCO Presentation Regulatory Strategy and Endpoints
Diluted EPS
$-2.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript
Confident tone Phase III OVATION 3 trial initiation OVATION 2 results and ASCO presentation IMNN-001 for ovarian cancer
Diluted EPS
$-3.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
Confident tone Imunon-001 OVATION 2 Phase 2 Results Phase 3 OVATION 3 Initiation Translational and Dose-Response Data
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript
Confident tone OVATION 2 Phase 2 results Commercial opportunity and market sizing TheraPlas platform and IL-12 mechanism
Diluted EPS
$-3.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript
Confident tone IMNN-101 COVID-19 vaccine and PlaCCine platform IMNN-001 / OVATION 2 Phase 2 ovarian cancer results Partnership strategy and non-dilutive funding
Diluted EPS
$-6.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript
Positive tone IMNN-001 / OVATION 2 ovarian cancer readout DNA-based technology platforms New CEO transition
Diluted EPS
$-6.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Imunon, Inc. (IMNN) Q4 2023 Earnings Call Transcript
Confident tone IMNN-101 Seasonal COVID-19 Vaccine and PlaCCine Platform Regulatory and FDA Engagement TheraPlas Platform and IL-12 Immunotherapy
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript
Diluted EPS
$-4.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Imunon, Inc. (IMNN) Q2 2023 Earnings Call Transcript
Diluted EPS
$-7.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Imunon, Inc. (IMNN) Q1 2023 Earnings Call Transcript
Diluted EPS
$-8.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Imunon, Inc. (IMNN) Q4 2022 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Imunon, Inc. (IMNN) Q3 2022 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Diluted EPS
$-11.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Imunon, Inc. (IMNN) Q2 2022 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Diluted EPS
$-11.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Imunon, Inc. (IMNN) Q1 2022 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Imunon, Inc. (IMNN) Q4 2021 Earnings Call Transcript
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Imunon, Inc. (IMNN) Q3 2021 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Imunon, Inc. (IMNN) Q2 2021 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Imunon, Inc. (IMNN) Q1 2021 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-19
Imunon, Inc. (IMNN) Q4 2020 Earnings Call Transcript
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-16
Imunon, Inc. (IMNN) Q3 2020 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-14
Imunon, Inc. (IMNN) Q2 2020 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Imunon, Inc. (IMNN) Q1 2020 Earnings Call Transcript
Revenue
$125,000
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Imunon, Inc. (IMNN) Q4 2019 Earnings Call
Revenue
$125,000*
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 749647 CUSIP 15117N701 Visit website Investor relations